TABLE 1 Data collection within the first year post-lung transplantation (LT) to predict chronic lung allograft dysfunction (CLAD) at year 3

	Pre-LT	Day 0, lung procurement and LT	6 months post-LT	12 months post-LT
Donor		Sex, age, comorbidities, gas exchange, HLA
Recipient clinicome	Sex, underlying diagnosis conducting to LT	Age, cold ischaemic time, ischaemia-reperfusion issue, centre effect	Home geolocalisation, rejection, infection episodes, bronchial complications, immunosuppressive regimen, lung function Outcomes at 3 years: healthy, RAS, BOS, deceased
Blood studies	Transcriptomics, HLA, HLA antibodies		HLA antibodies, transcriptomics, miRNA, proteomics, fresh and frozen PBMC subpopulations, T-lymphocytes subtyping	HLA antibodies, transcriptomics, miRNA, proteomics, fresh and frozen PBMC subpopulations, T-lymphocytes sub-typing
			Exome sequence analysis in patients reaching 3 years either healthy or with CLAD
BAL studies			Cell counts, proteomics, microbiote, macrophages subpopulations	Cell counts, proteomics, microbiote, macrophages subpopulations

BAL: bronchoalveolar lavage; HLA: human leukocyte antigen; RAS: restrictive allograft syndrome; BOS: bronchiolitis obliterans syndrome; miRNA: microRNA; PBMC: peripheral blood monocyte cells.